Oral lipid nanomedicines: Current status and future perspectives in cancer treatment

Moukhtari, Souhaila H. El; Rodríguez-Nogales, Carlos; Blanco-Prieto, María J.

doi:10.1016/j.addr.2021.03.004

Cited by 41 publications

(26 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Orally administered nanomedicines generally have low BA due to two barriers, mucus penetration and transepithelial transport. [ 2b,7b ] To tackle these barriers, the difficulty is that the requirements on the nanomedicine surface for efficient mucus penetration and transepithelial transport are opposite; that is, stealthy or nonfouling surface favors mucus penetration but hampers cellular uptake and transcytosis. [ 8 ] For instance, PEG‐based micelles are efficient in mucus penetration, [ 25 ] as shown in Figure 4a, but hardly taken up by villus cells (Figure 5a) and thus poor in intestinal absorption (Figure 4d,e) and BA (Figure 6a).…”

Section: Discussionmentioning

confidence: 99%

“…However, anticancer nanomedicines are generally limited to intravenous administration. [ 1 ] Given extensive research on oral nanomedicine, [ 2 ] there is no product clinically approved yet [ 2b,3 ] because orally administered nanomedicines typically suffer from very low BA and thus low efficacy. [ 3b,4 ]…”

Section: Introductionmentioning

confidence: 99%

“…An oral cancer nanomedicine must overcome a series of physiological and anatomical barriers in the gastrointestinal tract (GIT) [ 2a,5 ] and those from mesenteric capillaries to the tumor. [ 6 ] The intestinal mucus on the epithelia is the first barrier for nanomedicines to reaching intestinal villous cells.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mucus Penetrating and Cell‐Binding Polyzwitterionic Micelles as Potent Oral Nanomedicine for Cancer Drug Delivery

et al. 2022

View full text Add to dashboard Cite

Orally administrable anticancer nanomedicines are highly desirable due to their easy and repeatable administration, but are not yet feasible because the current nanomedicine cannot simultaneously overcome the strong mucus and villi barriers and thus have very low bioavailability (BA). Herein, this work presents the first polymeric micelle capable of fast mucus permeation and villi absorption and delivering paclitaxel (PTX) efficiently to tumors with therapeutic efficacy even better than intravenously administered polyethylene glycol based counterpart or free PTX. Poly[2‐(N‐oxide‐N,N‐diethylamino)ethyl methacrylate] (OPDEA), a water‐soluble polyzwitterion, is highly nonfouling to proteins and other biomacromolecules such as mucin but can weakly bind to phospholipids. Therefore, the micelle of its block copolymer with poly(ε‐caprolactone) (OPDEA‐PCL) can efficiently permeate through the viscous mucus and bind to villi, which triggers transcytosis‐mediated transepithelial transport into blood circulation for tumor accumulation. The orally administered micelles deliver PTX to tumors, efficiently inhibiting the growth of HepG2 and patient‐derived hepatocellular carcinoma xenografts and triple‐negative breast tumors. These results demonstrate that OPDEA‐based micelles may serve as an efficient oral nanomedicine for delivering other small molecules or even large molecules.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mucus Penetrating and Cell‐Binding Polyzwitterionic Micelles as Potent Oral Nanomedicine for Cancer Drug Delivery

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 19 , 20 Oral route can be utilised to target a specific location in the GIT following proper design of the drug or the delivery carrier. 21 Several studies utilised oral route to target CRC throughout the rational design of cancer target discovery and development (CTDD). 22 …”

Section: Introductionmentioning

confidence: 99%

Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment

Choukaife¹,

Seyam²,

Alallam³

et al. 2022

IJN

View full text Add to dashboard Cite

As per the WHO, colorectal cancer (CRC) caused around 935,173 deaths worldwide in 2020 in both sexes and at all ages. The available anticancer therapies including chemotherapy, radiotherapy and anticancer drugs are all associated with limited therapeutic efficacy, adverse effects and low chances. This has urged to emerge several novel therapeutic agents as potential therapies for CRC including synthetic and natural materials. Orally administrable and targeted drug delivery systems are attractive strategies for CRC therapy as they minimize the side effects, enhance the efficacy of anticancer drugs. Nevertheless, oral drug delivery till today faces several challenges like poor drug solubility, stability, and permeability. Various oral nano-based approaches and targeted drug delivery systems have been developed recently, as a result of the ability of nanoparticles to control the release of the encapsulant, drug targeting and reduce the number of dosages administered. The unique physicochemical properties of chitosan polymer assist to overcome oral drug delivery barriers and target the colon tumour cells. Chitosan-based nanocarriers offered additional improvements by enhancing the stability, targeting and bioavailability of several anti-colorectal cancer agents. Modified chitosan derivatives also facilitated CRC targeting through strengthening the protection of encapsulant against acidic and enzyme degradation of gastrointestinal track (GIT). This review aims to provide an overview of CRC pathology, therapy and the barriers against oral drug delivery. It also emphasizes the role of nanotechnology in oral drug targeted delivery system and the growing interest towards chitosan and its derivatives. The present review summarizes the relevant works to date that have studied the potential applications of chitosan-based nanocarrier towards CRC treatment.

show abstract

“…The oral administration of drugs is preferred in human and veterinary medicine thanks to many practical benefits as high compliance, better disease management, reduced costs, easy of distribution and selling in the markets [1]. However, this route o administration is often not possible due to plethora of drawbacks related to drugs stability and degradability, besides toxicity and poor bioavailability [2,3].…”

Section: Introductionmentioning

confidence: 99%

Efficient Treatment of Fish Intestinal Parasites Applying Biocompatible Membrane-penetrating Oral Drug Delivery Nanoparticles

Mathews¹,

Patta²,

Madrid³

et al. 2021

Preprint

View full text Add to dashboard Cite

Nanodelivery of drugs aims to ensure drug stability in the face of adverse biochemical conditions in the course of administration, concomitant with appropriate pharmacological action provided by delivery at the targeted site. In this study, the application potential of nanoparticles produced with biopolymers chitosan-N-arginine and alginate as an oral drug delivery material is evaluated. Being both macromolecules weak polyelectrolytes, the bioparticle presents strong thermodynamic interaction with a biological model membrane consisting of charged lipid liposome bilayer, leading to membrane disruption and membrane penetration of the bioparticles in ideal conditions of pH corresponding to the oral route. The powder form of the bioparticle was obtained by lyophilization and with a high percentage of entrapment of the anthelmintic drug praziquantel. In vivo studies were conducted with oral administration to Corydoras schwartzi fish with high intensity of intestinal parasites infection. The in vivo experiments confirmed the mucoadhesive and revealed membrane-penetrating properties of the bioparticle by translocating the parasite cyst, which provided target drug release and reduction of over 97% of the fish intestinal parasites. Thus, it was evidenced that the bioparticle was effective in transporting and releasing the drug to the target, providing an efficient treatment.

show abstract

Oral lipid nanomedicines: Current status and future perspectives in cancer treatment

Cited by 41 publications

References 155 publications

Mucus Penetrating and Cell‐Binding Polyzwitterionic Micelles as Potent Oral Nanomedicine for Cancer Drug Delivery

Mucus Penetrating and Cell‐Binding Polyzwitterionic Micelles as Potent Oral Nanomedicine for Cancer Drug Delivery

Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment

Efficient Treatment of Fish Intestinal Parasites Applying Biocompatible Membrane-penetrating Oral Drug Delivery Nanoparticles

Contact Info

Product

Resources

About